Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Prostate Cancer Med Orgovyx Approved in Canada: Sumitomo
October 25, 2023
- Sawai Fudged Quality Tests of Gastritis Drug for 8 Years, Awaiting Penalty Decision
October 24, 2023
- Janssen Files PAH Fixed-Dose Combo Drug in Japan
October 24, 2023
- Enhertu Gets EU Nod for NSCLC, Triggers US$75 Million Milestone
October 24, 2023
- Pfizer Japan Recalling Docetaxel IV Infusion 20 mg/2 mL
October 23, 2023
- Daiichi Sankyo, Merck in Global ADC Deal Worth Up to US$22 Billion
October 23, 2023
- Myfembree Gets Canada Nod for Uterine Fibroid, Endometriosis
October 23, 2023
- Takeda’s Adcetris Approved in Europe for 7th Indication
October 23, 2023
- Medicon, Mucodyne among Drugs Subject to MHLW’s Ramp-Up Request
October 20, 2023
- Oncology, Cell & Gene Therapies Key Priorities for Bayer Co.Labs: Global Head
October 20, 2023
- Kyowa Kirin Set to Gain Tens of Billions of Yen in Sales from Orchard Acquisition
October 20, 2023
- Takeda to Pay 130 Million Euro to Settle Tax Row over Shire-AbbVie Breakup Fee
October 19, 2023
- Takeda’s 1st Cell Therapy Alofisel Misses Goal in Key PIII Study
October 19, 2023
- Diazepam Nasal Spray Shows Efficacy in PIII Interim Analysis: Aculys
October 19, 2023
- Fuji Pharma/M3’s Dysmenorrhea Drug Filed in Japan, 2024 Rollout Targeted
October 19, 2023
- Herceptin Biosimilars Get Colorectal Cancer Nod: Celltrion, Nippon Kayaku
October 19, 2023
- Daiichi Sankyo Ordered to Pay 8% Royalty to Seagen in ADC Patent Row
October 19, 2023
- BMS Looks to Double Japan Biz in Next 10 Years with Partnership as a Pillar
October 19, 2023
- Broader Use of Blood Biomarkers Key to Maximizing Leqembi’s Value: Eisai Exec
October 18, 2023
- IBM Leads Development of Integrated Drug Supply Database for Wholesaler Reps, Pharmacists
October 18, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…